Compare · BSX vs LNSR
BSX vs LNSR
Side-by-side comparison of Boston Scientific Corporation (BSX) and LENSAR Inc. (LNSR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and LNSR operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $63.97B, about 863.5x LNSR ($74.1M).
- Over the past year, BSX is down 55.9% and LNSR is down 52.3% - LNSR leads by 3.5 points.
- BSX has hit the wire 4 times in the past 4 weeks while LNSR has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 3 for LNSR).
- Company
- Boston Scientific Corporation
- LENSAR Inc.
- Price
- $44.38+0.50%
- $5.82-3.96%
- Market cap
- $63.97B
- $74.1M
- 1M return
- +1.88%
- -18.26%
- 1Y return
- -55.85%
- -52.33%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 3
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
LENSAR Inc.
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Latest BSX
- Barclays initiated coverage on Boston Scientific with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update
- Boston Scientific downgraded by Citigroup with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
- SEC Form 4 filed by Boston Scientific Corporation
- Director Morano Susan E bought $100,408 worth of shares (2,040 units at $49.22), increasing direct ownership by 17% to 13,784 units (SEC Form 4)
- Boston Scientific Corporation filed SEC Form 8-K: Other Events
Latest LNSR
- SEC Form 10-Q filed by LENSAR Inc.
- LENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LENSAR® Reports Second Quarter 2026 Results and Provides Business Update
- LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
- SEC Form DEFA14A filed by LENSAR Inc.
- SEC Form DEF 14A filed by LENSAR Inc.
- Director Hammer Todd B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Director Ellis Thomas B was granted 17,421 shares, increasing direct ownership by 45% to 56,083 units (SEC Form 4)
- Principal Accounting Officer Wong Kendra was granted 13,066 shares, increasing direct ownership by 30% to 56,481 units (SEC Form 4)